肥大细胞疾病中的嗜酸性粒细胞增多。
Eosinophilia in mast cell disease.
机构信息
Division of Allergy and Inflammation, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215, USA.
Division of Allergy and Inflammation, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue CLS943, Boston, MA 02215, USA; Division of Infectious Diseases, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue CLS943, Boston, MA 02215, USA.
出版信息
Immunol Allergy Clin North Am. 2014 May;34(2):357-64. doi: 10.1016/j.iac.2014.01.013. Epub 2014 Mar 13.
Abstract
Eosinophils and mast cells coexist in clonal and nonclonal disorders. The interplay between these cells is complex and not fully understood. Discussed are both allergic/nonclonal disorders in which both cell types are increased in number are likely to play a role in pathogenesis and clonal disorders in which both cell types are affected and play key roles in pathogenesis. Finally, some treatment options, keeping both disorders in mind, are discussed. Future directions in thinking about these disorders are also briefly explored.
摘要
嗜酸性粒细胞和肥大细胞共存于克隆和非克隆疾病中。这些细胞之间的相互作用很复杂，目前尚未完全了解。本文讨论了既涉及嗜酸性粒细胞和肥大细胞数量增加的过敏性/非克隆疾病，也讨论了涉及这两种细胞且在发病机制中起关键作用的克隆疾病。最后，还讨论了一些考虑到这两种疾病的治疗选择。本文还简要探讨了对这些疾病的思考的未来方向。
相似文献
1
Eosinophilia in mast cell disease.肥大细胞疾病中的嗜酸性粒细胞增多。
Immunol Allergy Clin North Am. 2014 May;34(2):357-64. doi: 10.1016/j.iac.2014.01.013. Epub 2014 Mar 13.
2
CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy.CHIC2缺失作为FIP1L1-PDGFRA融合的替代指标，见于伴有嗜酸性粒细胞增多的系统性肥大细胞增多症，并可预测对甲磺酸伊马替尼治疗的反应。
Blood. 2003 Nov 1;102(9):3093-6. doi: 10.1182/blood-2003-05-1627. Epub 2003 Jul 3.
3
Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial.甲磺酸伊马替尼治疗系统性肥大细胞增多症：一项II期试验
Cancer. 2006 Jul 15;107(2):345-51. doi: 10.1002/cncr.21996.
4
Cessation of imatinib mesylate may lead to sustained hematologic and molecular remission in FIP1L1-PDGFRA-mutated hypereosinophilic syndrome.甲磺酸伊马替尼的停药可能导致FIP1L1-PDGFRA突变的嗜酸性粒细胞增多综合征出现持续的血液学和分子学缓解。
Am J Hematol. 2014 Jan;89(1):115. doi: 10.1002/ajh.23588. Epub 2013 Oct 15.
5
FIP1L1-PDGFRalpha in hypereosinophilic syndrome and mastocytosis.高嗜酸性粒细胞综合征和肥大细胞增多症中的FIP1L1-PDGFRα
Hematol J. 2004;5 Suppl 3:S133-7. doi: 10.1038/sj.thj.6200439.
6
Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness.血清类胰蛋白酶水平升高可识别出一部分患有特发性嗜酸性粒细胞增多综合征骨髓增殖变异型的患者，该变异型与组织纤维化、预后不良及伊马替尼反应性相关。
Blood. 2003 Jun 15;101(12):4660-6. doi: 10.1182/blood-2003-01-0006. Epub 2003 Apr 3.
7
Systemic mastocytosis (SM) associated with chronic eosinophilic leukemia (SM-CEL): detection of FIP1L1/PDGFRalpha, classification by WHO criteria, and response to therapy with imatinib.与慢性嗜酸性粒细胞白血病相关的系统性肥大细胞增多症（SM-CEL）：FIP1L1/PDGFRα的检测、按世界卫生组织标准分类以及对伊马替尼治疗的反应
Leuk Res. 2006 Sep;30(9):1201-5. doi: 10.1016/j.leukres.2005.11.014. Epub 2006 Jan 6.
8
FIP1L1-PDGFRα-positive hypereosinophilic syndrome in childhood: a case report and review of literature.儿童FIP1L1-PDGFRα阳性高嗜酸性粒细胞综合征：一例报告并文献复习
J Pediatr Hematol Oncol. 2014 Jan;36(1):e28-30. doi: 10.1097/MPH.0b013e31827e6386.
9
Murine model of hypereosinophilic syndromes/chronic eosinophilic leukemia.嗜酸性粒细胞增多综合征/慢性嗜酸性粒细胞白血病的小鼠模型
Int Arch Allergy Immunol. 2009;149 Suppl 1:102-7. doi: 10.1159/000211381. Epub 2009 Jun 3.
10
Antitumor activity of S116836, a novel tyrosine kinase inhibitor, against imatinib-resistant FIP1L1-PDGFRα-expressing cells.新型酪氨酸激酶抑制剂S116836对表达伊马替尼耐药的FIP1L1-PDGFRα细胞的抗肿瘤活性。
Oncotarget. 2014 Nov 15;5(21):10407-20. doi: 10.18632/oncotarget.2090.
引用本文的文献
1
Depletion of eosinophils during sensitization but not challenge phase in mice blocks the development of food allergy early in life.在小鼠致敏阶段而非激发阶段使嗜酸性粒细胞耗竭，可在生命早期阻止食物过敏的发生。
J Immunol. 2025 Apr 1;214(4):582-594. doi: 10.1093/jimmun/vkae044.
2
Hematological Neoplasms with Eosinophilia.伴有嗜酸性粒细胞增多的血液系统肿瘤
Cancers (Basel). 2024 Jan 12;16(2):337. doi: 10.3390/cancers16020337.
3
Infantile Urticaria Pigmentosa with Eosinophilic Infiltration: A Case Report.伴有嗜酸性粒细胞浸润的婴儿色素性荨麻疹：一例报告
Indian J Dermatol. 2022 Jul-Aug;67(4):482. doi: 10.4103/ijd.ijd_887_20.
4
[Spectrum of gene mutations and clinical features in adult acute myeloid leukemia with normal karyotype].[核型正常的成人急性髓系白血病的基因突变谱及临床特征]
Zhonghua Xue Ye Xue Za Zhi. 2021 May 14;43(5):420-423. doi: 10.3760/cma.j.issn.0253-2727.2022.05.012.
5
Characterization of skin surface and dermal microbiota in dogs with mast cell tumor.犬肥大细胞瘤皮肤表面和真皮微生物组的特征。
Sci Rep. 2020 Jul 28;10(1):12634. doi: 10.1038/s41598-020-69572-0.
6
Gastrointestinal Manifestations of Hypereosinophilic Syndromes and Mast Cell Disorders: a Comprehensive Review.高嗜酸性粒细胞综合征和肥大细胞疾病的胃肠道表现：全面综述。
Clin Rev Allergy Immunol. 2019 Oct;57(2):194-212. doi: 10.1007/s12016-018-8695-y.
7
Mastocytosis: from a Molecular Point of View.肥大细胞增多症：从分子角度看。
Clin Rev Allergy Immunol. 2018 Jun;54(3):397-411. doi: 10.1007/s12016-017-8619-2.
8
Eosinophilia.嗜酸性粒细胞增多
Prim Care. 2016 Dec;43(4):607-617. doi: 10.1016/j.pop.2016.07.010. Epub 2016 Oct 14.
本文引用的文献
1
Mastocytosis: update on pharmacotherapy and future directions.肥大细胞增多症：药物治疗的最新进展和未来方向。
Expert Opin Pharmacother. 2013 Oct;14(15):2033-45. doi: 10.1517/14656566.2013.824424.
2
Anti-IL-5 therapy reduces mast cell and IL-9 cell numbers in pediatric patients with eosinophilic esophagitis.抗白细胞介素-5 治疗可减少嗜酸细胞性食管炎患儿的肥大细胞和白细胞介素-9 细胞数量。
J Allergy Clin Immunol. 2013 Jun;131(6):1576-82. doi: 10.1016/j.jaci.2013.02.042. Epub 2013 Apr 25.
3
Interacting mast cells and eosinophils acquire an enhanced activation state in vitro.在体外，相互作用的肥大细胞和嗜酸性粒细胞获得增强的激活状态。
Allergy. 2013 Feb;68(2):171-9. doi: 10.1111/all.12059. Epub 2012 Dec 4.
4
Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial.美泊利单抗治疗严重嗜酸性粒细胞性哮喘（DREAM）：一项多中心、双盲、安慰剂对照试验。
Lancet. 2012 Aug 18;380(9842):651-9. doi: 10.1016/S0140-6736(12)60988-X.
5
Mast cells and eosinophils in mastocytosis, chronic eosinophilic leukemia, and non-clonal disorders.肥大细胞和嗜酸性粒细胞在肥大细胞增多症、慢性嗜酸性粒细胞白血病和非克隆性疾病中的作用。
Semin Hematol. 2012 Apr;49(2):128-37. doi: 10.1053/j.seminhematol.2012.01.007.
6
Use of pegylated interferon in hypereosinophilic syndrome.聚乙二醇干扰素在高嗜酸性粒细胞综合征中的应用。
Leuk Res. 2012 Feb;36(2):192-7. doi: 10.1016/j.leukres.2011.09.026. Epub 2011 Nov 26.
7
Improved detection of the KIT D816V mutation in patients with systemic mastocytosis using a quantitative and highly sensitive real-time qPCR assay.采用定量、高灵敏度实时 qPCR 法检测系统性肥大细胞增多症患者 KIT D816V 突变。
J Mol Diagn. 2011 Mar;13(2):180-8. doi: 10.1016/j.jmoldx.2010.10.004.
8
Physical interactions between mast cells and eosinophils: a novel mechanism enhancing eosinophil survival in vitro.肥大细胞与嗜酸性粒细胞之间的物理相互作用：一种增强嗜酸性粒细胞体外存活的新机制。
Allergy. 2011 Mar;66(3):376-85. doi: 10.1111/j.1398-9995.2010.02494.x. Epub 2010 Oct 26.
9
How I treat patients with advanced systemic mastocytosis.我如何治疗晚期系统性肥大细胞增多症患者。
Blood. 2010 Dec 23;116(26):5812-7. doi: 10.1182/blood-2010-08-292144. Epub 2010 Sep 20.
10
Involvement of mast cells in eosinophilic esophagitis.肥大细胞在嗜酸性粒细胞性食管炎中的作用。
J Allergy Clin Immunol. 2010 Jul;126(1):140-9. doi: 10.1016/j.jaci.2010.04.009. Epub 2010 Jun 9.
Zotero 插件